newsfilter
← Latest News
GlobeNewswire·

Entrada Therapeutics Reports First Quarter 2024 Financial Results

– Initiated dosing of the fourth and final cohort of Phase 1 clinical trial of ENTR-601-44 for the potential treatment of DMD with data readout on track for October of 2024 – – Achieved $75 million milestone payment